Oklahoma Right to Try (SB 933): Individualized Treatment Access

Announcement · October 2026

Oklahoma’s Right to Try for Individualized Treatments Act, Senate Bill 933, takes effect November 1, 2026. Beginning that date, Venturis Clinic in Oklahoma City will offer SB 933 screening and access navigation, built on genetic testing and genome sequencing, for patients with serious illness who have run out of approved options. Screening opens November 1, and you can join the list today.

What SB 933 does

SB 933 gives eligible Oklahoma patients a state-law pathway to request treatments made specifically for them, based on their own genetic profile, when approved treatments have not worked and a clinical trial isn’t available. It protects physicians who recommend these treatments in good faith from disciplinary action for that recommendation, and it bars state officials from blocking an eligible patient’s access.

Who may be eligible

• You have a life-threatening or severely debilitating illness, attested by your treating physician.
• You have considered or tried all approved treatment options.
• You are unable to participate in a clinical trial for your condition.
• A licensed physician (MD or DO) recommends an individualized investigational treatment.
• You give written informed consent.

What counts as an individualized treatment

Under the national model the Oklahoma act is based on, an individualized investigational treatment is a drug, biological product or device that is unique and produced exclusively for one patient based on that patient’s own genetic profile. Examples include individualized gene therapies, antisense oligonucleotides and individualized neoantigen vaccines. These treatments are provided through eligible facilities, defined as institutions operating under a Federalwide Assurance for the protection of human subjects.

What SB 933 does not do

• It does not approve off-the-shelf stem cell or exosome products, or change federal FDA law.
• It does not require any manufacturer, physician, hospital or facility to provide a treatment.
• It does not require insurers, employers or the state to pay. Patients are generally responsible for the cost.
• It does not guarantee that a treatment will work.

What Venturis Clinic will offer

1. Genetic testing and genome sequencing through CLIA-certified laboratories, so you and your physician have the genetic profile individualized treatment depends on.
2. Eligibility screening: we review your diagnoses and treatment history against the law’s criteria and document the approved options you have tried.
3. Access navigation: we identify eligible facilities, manufacturers, clinical trials and expanded-access programs that may fit your situation.
4. Physician coordination: our physician medical director (MD or DO), or your own treating physician, evaluates whether to recommend treatment. Nurse practitioners and physician assistants on your care team support screening, records and follow-up.
5. Informed consent support: plain-language review of the risks, the likely and worst-case outcomes, and the costs, before you sign anything.
6. Case documentation: patients who choose to can have their course documented in our voluntary case documentation program.

Beyond SB 933, we help patients understand their lawful options for stem cell and exosome therapies under FDA rules, including clinical trials, expanded access and the federal Right to Try Act.

Join the SB 933 screening list

Call (405) 848-7246 or send us a message and ask to be added to the SB 933 screening list. We’ll schedule a free 15-minute discovery call, and screening appointments begin November 1, 2026.

FAQ

Can I start now?

Genetic testing is available now. SB 933 screening and coordination begin November 1, 2026, when the law takes effect.

Does SB 933 cover stem cells or exosomes?

Only if the treatment is produced uniquely for you from your genetic profile. Standard donor stem cell and exosome products are covered by federal pathways instead. Compare the pathways.

Who can recommend treatment under SB 933?

A licensed physician, meaning an MD or DO. That can be our physician medical director or your own treating physician. Nurse practitioners and physician assistants can help with screening and coordination, but the recommendation itself comes from a physician.

Do I need a diagnosis first?

Yes. Eligibility depends on a diagnosed life-threatening or severely debilitating illness, attested by your treating physician.

Is this a clinical trial?

No. SB 933 is a treatment-access law, not a research study.

Educational information only, not legal or medical advice. Eligibility is determined by the treating physician, the eligible facility and the manufacturer under the final enacted text of SB 933. Venturis Clinic does not manufacture investigational treatments and cannot guarantee access. Sources: Oklahoma Senate and House press releases on SB 933 (2026); 21 CFR 312.81.